Sipuleucel-T: all 23 studies that test it
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNot yet recruitingNCT07756593Phase 1
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TRecruitingNCT06134232Phase 2
- Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCRecruitingNCT06100705Phase 2
- Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerCompletedNCT03686683Phase 3Results posted
- A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT01981122Phase 2Results posted
- Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)CompletedNCT01818986Phase 2Results posted
- Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerCompletedNCT01487863Phase 2Results posted
- Sipuleucel-T Manufacturing Demonstration StudyCompletedNCT01477749Phase 2Results posted
- Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate CancerCompletedNCT01431391Phase 2Results posted
- Sipuleucel-T in Metastatic Castrate Resistant Prostate CancerTerminatedNCT01338012Phase 2Results posted
- Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate CancerCompletedNCT01133704Phase 3Results posted
- Open Label Study of Sipuleucel-T in Metastatic Prostate CancerCompletedNCT00901342Phase 2Results posted
- PROvenge Treatment and Early Cancer TreatmentCompletedNCT00779402Phase 3Results posted
- Sipuleucel-T as Neoadjuvant Treatment in Prostate CancerCompletedNCT00715104Phase 2Results posted
- To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) AntigenCompletedNCT00715078Phase 2Results posted
- Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyCompletedNCT00065442Phase 3Results posted
- Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005947Phase 3Results posted
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate CancerActive, not recruitingNCT05806814Phase 1
- Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerCompletedNCT03024216Phase 1
- Docetaxel Followed by Provenge in Metastatic Prostate CancerWithdrawnNCT02793765Phase 2
- Provenge Followed by Docetaxel in Castration-Resistant Prostate CancerWithdrawnNCT02793219Phase 2
- Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate CancerCompletedNCT02036918Phase 1
- Sipuleucel-T and Ipilimumab for Advanced Prostate CancerCompletedNCT01832870Phase 1